PRKAA2 and depressive symptom measurement: There is evidence to support that AMPK activation signaling underlies the effects of this drug in several pathologies including insulin resistance, diabetes and chronic neuropathic pain (Figure 1), although the role of AMPK in pain-related anxiety/depression and cognitive impairment is unknown.